MIFEPRISTONE AND UTERINE MYOMA


Дәйексөз келтіру

Толық мәтін

Аннотация

In the literature review questions of pathogenesis of uterine myoma LMM, with accent on hormonal regulation of tumours proliferation are considered. The doubtless role of a progesterone in the pathogenesis of myomas is an adequate substantiation of application antigestagenes in disease therapy. Successful clinical application mifepristone confirms the leading part of a progesterone in the control of growth of a myoma. Now medicamentous treatment of a myoma of a uterus is not ideal, nevertheless, from all spectrum of offered approaches use antigestagenes (mifepristone), considering its high efficiency and safety, it has appeared the most comprehensible.

Авторлар туралы

E Kareva

Elena Kareva

Әдебиет тізімі

  1. Вихляева Е.М. Руководство по эндокринной гинекологии. М., 2000. С. 424-87.
  2. Карева Е.Н. Молекулярные механизмы действия женских половых стероидов и их антагонистов. Автореф. дисс. докт. мед. наук. М., 2003. 55 с.
  3. Краснопольский В.И., Логутова Л.С., Буянова С.Н. и др. Хирургическая и акушерская тактика при сочетании беременности с опухолями половых органов // Акушерство и гинекология. 2002. № 2. С. 41-5.
  4. Кулаков В.И., Шилова М.Н. Применение агонистов гондотропин-рилизинг-гормона для лечения миомы матки // Акушерство и гинекология. 1998. № 6.
  5. Савицкий Г.А. Миома матки. СПб., 2000. 214 с.
  6. Самойлова Т.Е., Гус А.И., Аль-Сейкал Т.С. Применение мифепристона в лечении лейомиомы матки. Тезисы второго Российского Конгресса по менопаузе и гинекологической эндокринологии. 14-17 сентября 2004.
  7. Сергеев П.В., Карева Е.Н., Ткачева Н.Ю. Сравнительный анализ рецепторов прогестерона и эстрадиола при миоме у человека // Бюллетень экспериментальной биологии и медицины. 1994, Т. CXVII. № 7. С. 33-4.
  8. Сергеев П.В., Карева Е.Н., Ткачева Н.Ю., Высоцкий М.М. Прогестерон: рецепторный механизм действия в норме и при опухолевом росте (обзор) // Акушерство и гинекология. 1994. № 5. С. 6-9.
  9. Pan Q. Chegini N MicroRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. Molecular Human Reproduction 2010;16(3):215-27.
  10. Hoekstra AV, Sefton EC, Berry E, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. Clin Endocrinol Metab 2009;94(5):1768-74.
  11. Bagaria M, Suneja A, Vaid NB, et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009;49(1):77-83.
  12. Baschinsky DY, Isa A, Niemann TH, et al. Diffuse Leiomyomatosis of the uterus. A case report with clonality analysis. Hum Pathol 2000;31(1 1):1430-32.
  13. Benassayag C, Leroy MJ, Rigourd V, et al. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium:pregnancy and leiomyoma. Am J Physiol 1999;276(6 Pt 1):El 11 2-El1 18.
  14. Blake RE. Leiomyomata uteri: hormonal and molecular determinants of growth J Natl Med Assoc 2007;99(10):1170-84.
  15. Boman K, Strang P, Backstrom T, et al. The influence of progesterone and androgens on the growth of endometrial carcinoma. J Cancer 1993;71(11):3565-69.
  16. Cheng M-H, Wang P-H. Uterine myoma: a condition amendable to medical therapy? Expert Opin Emerging Drugs 2008;13(1):119-33.
  17. Chrapusta S, Sieinski W, Konopka B, et al. Estrogen and progestin receptor levels in uterine leiomyomata: relation to the tumour histology and the phase of menstrual cycle. J Eur J Gynaecol Oncol 1900;11(5):381-87.
  18. Chwalisz K, Parker L, Williamson S. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM). J Soc Gynecol Invest 2003;10:301A.
  19. Dawood MA, Khan-Dawood FS. Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas. Fertil Steril 1994;61:617-21.
  20. De Leo V, La Marca A, Morgante G, et al. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Fertil Steril 2001;75:632-33.
  21. Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12(3):227-33.
  22. Engman M, Granberg S, Williams ARW, et al.Mifepristone for Treatment of Uterine Leiomyoma. A Prospective Randomized Placebo Controlled Trial. Human Reproduction 2009;24(8):1870-79.
  23. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037-54.
  24. Fleischer R, Weston GC, Wood C, et al. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Res Clin Obst Gynaecol 2008;22(4):603-14.
  25. Gross KL, Stovall DW, Chavez NL, et al. Management options for uterine fibroids. Clin Obstet Gynaecol 2001;44:335-85.
  26. Gustavsson I, Englund K, et al. Tissue differences but limited sex steroid responsiveness of c-fos and c-jun in human fibroids and myometrium. Mol Hum Reprod 2000;6:55-9.
  27. http://microna.sanger.ac.uk/; http://www.targetscan.org/; http://pictar.bio.nyu.edu/ микро РНК.
  28. Imir AG, Lin Z, Yin P, et al. Aromatase Expression in Uterine Leiomyomata is regulated by Proximal Promoters 1.3/11. J Clin Endocrin Metab. First published ahead of print March 6, 2007:2006-482.
  29. Jeyasuria P, Wetzel J, Bradley M, et al. Progesterone-regulated caspase 3 action in the mouse may play a role in uterine quiescence during pregnancy through fragmentation of uterine myocyte contractile proteins. Biol Reprod 2009;80(5):928-34.
  30. Kawaguchi K, Fujii S, Konishi I, et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. J Virchows Arch A Pathol Anat Histopathol 1991;419(4):309-15.
  31. Kovacs KA, Oszter A, Gocze PM, et al. Comparative analysis of cyclin Dl and oestrogen receptor ({alpha} and {beta}) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod 2001;7(1):1085-91.
  32. Kurachi O, Matsuo H, Samoto T, et al. Tumor necrosis factor- expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab 2001;86:2275-80.
  33. Lakimiuk Al, Bogusiewicz M, Tarkowski R, et al. Estrogen receptor a and B expression in uterine leiomyoma from premenopausal women. Fertil and Steril 2004;82(Suppl. 3):1244-49.
  34. Lethaby AE, Vollenhoven BJ, An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Research Clin Obst Gynaecol 2008;22(2):307-31.
  35. Lobel MK, Somasundaram P, Morton CC. The genetic heterogeneity of uterine leiomyomata. Obstet Gynecol Clin North Am 2006;33(1):13-39.
  36. Maruo T, Ohara N, Wang J, et al. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004;10(3):207-20.
  37. Mashal RD, Fejzo ML, Friedman AJ, et al. Analysis of androgen receptor DNA reveals the independent clonal orgins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 1994;1(1):1-6.
  38. Matsuo H, Matsuo H, Maruo T, et al. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endoclinol Metab 1999;82:293-99.
  39. Murphy AA, Kettel LM, Morales AJ, et al. Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76(2):51317.
  40. Murphy AA, Morales AJ, Kettel LM, et al. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995;64:187-90.
  41. Narayanan R, Adigun AA, Edwards DP, et al. Cyclin-Dependent Kinase Activity Is Required for Progesterone Receptor Function: Novel Role for Cyclin A/Cdk2 as a Progesterone Receptor Coactivator. Mol Cell Biol 2005;25(1):264-77.
  42. Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium durng the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-50.
  43. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obst Gyn 2008;22:571-88.
  44. Paquette B, Bisson M, Baptiste C, et al. Invasiveness of breast cancer cells MDA-MB-231 through extracellular matrix is increased by the estradiol metabolite 4-hydroxyestradiol. Int J Cancer 2005;113:706-11.
  45. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertility Sterility 2007;87(4):725-36.
  46. Peng L, Wen Y, Han Y, et al.Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertility Sterility 2009;91(6):2664-75.
  47. Hoekstra AV, Sefton EC, Berry E, Lu Z, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 2009;94:1768-74.
  48. Ramachandran S, Kwon K-Y, Shin S-J, et al. Cyclin-Dependent Kinase Inhibitor p27Kip1 Controls Growth and Cell Cycle Progression in Human Uterine Leiomyoma. J Korean Med Sci 2008;23:667-73.
  49. Rein MS, Nowak RA. Biology of uterine myomas and myometrium in vitro. In BarBieri RL (ed) Seminars in Productive Endocrinology. Thieme, New York, 1992;310-19.
  50. Rein MS, Powell WL, Walters FC, et al. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod 1998;4(1):83-6.
  51. Sankaran S, Manyonda IT: Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22(4):655-76.
  52. Shozu M, Murakami K, Segawa T, et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003;79:628-31.
  53. Steinauer J, Pritts EA, Jackson R, et al. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obst Gynecol 2004;103(6):1331-36.
  54. Trowbridge JM, Rogatsky I, Garabedian MJ. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2complex. Proc Natl Acad Sci USA 1997;94(19):10132-37.
  55. Wei JJ, Chiriboga L, Khush M. Expression profile of the tumorigenic factors associated with tumor size and sex steroids hormone status in uterine leiomyomata. Fertil Steril 2005;84:474-84.
  56. Weston G, Trajstman AC, Gargett CE, et al. Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Human Reprod 2003;9(9):541-49.
  57. Xu Q, Ohara N, Maruo T, et al. Progesterone receptor modulator CDB2914 down-regulates VEGF, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21:2408-16.
  58. Yin P, Lin Z, Cheng Y-H, et al. Progesterone Receptor Regulates Bcl-2 Gene Expression through Direct Binding to Its Promoter Region in Uterine Leiomyoma. Cells J Clin Endocrinol Metab 2007;92(11):4459-66.
  59. Yu L, Saile K, Swartz CD, et al. Differential Expression of Receptor Tyrosine Kinases (RTKs) and IGF-I Pathway Activation in Human Uterine Leiomyomas. Molmed 2008;14(5-6):264-75.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>